Spinnovation launches biologics analysis division

Published: 8-Apr-2011
Finance Analysis Pharmaceutical

Spinnovation Biologics to provide profiling and characterisation of biologics

Spinnovation Analytical, a Dutch contract research organisation, has launched a new division called Spinnovation Biologics, which will provide spent culture media analysis and profiling and characterisation of biologics and biosimilar drugs.

Frederic Girard, chief executive of the Nijmegen-based nuclear magnetic resonance spectroscopy (NMR) specialist, said spent media analysis with Spedia-NMR would be the new company’s core service.

‘Spedia-NMR is unique and can deliver a step-fold increase in throughput and detail over standard methods, in as few as five working days,’ he said.

Spinnovation Biologics will also offer process and product bioanalysis, enabling clients to benefit from advanced insights into cell culture to enhance productivity, scalability, and reliability for QA/QC control, cGMP production and support Quality by Design.

In addition to Spedia-NMR technology, Spinnovation Biologics has a broad spectrum of analysis methods in house, including: LC-MS, LC-NMR, LC-SPE-NMR and LC-SPE-NMR-MS.

See more

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

Read more
To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands

Trending Articles

  1. Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025 The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
  2. Agarose Bead Technologies marks 25 years with $10m global expansion plan The Spanish agarose resin specialist will expand into the US and India, invest in scalable bioprocessing technologies and enhance sustainability across its European facilities to meet growing demand for advanced therapy purification
  3. Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
  4. Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
  5. MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands
Analysis

Spinnovation Biologics predicts bioproduction performance

With the launch of Spedia-Predict
Pharmaceutical

Spinnovation introduces approach to improve biologicals manufacturing processes

Spinnovation technology delivers optimal cell viability and density, with the right safety and quality parameters in a short time frame
Analysis

Spinnovation Biologics offers service choices to meet individual analysis needs for bioprocess optimisation

Unique mix of services delivers essential support for the development and manufacture of biologics
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Finance

Lonza to expand bioscience testing offering with the acquisition of Redberry

Acquisition to include Red One solid-phase cytometry platform for rapid sterility and bioburden testing, which expands Lonza’s portfolio of automated, scalable solutions for pharmaceutical quality control (QC)
Finance

Shilpa Medicare opens flow chemistry manufacturing centre

The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists
Subscribe now